Related Experiment Video
Updated: Jul 10, 2026
09:17
Psychophysical Tracking Method to Measure Taste Preferences in Children and Adults
Published on: July 16, 2016
Sugar and sugar substitutes. Comparisons and indications.
Postgraduate Medicine
|August 1, 1987
Summary
Sugar substitutes like aspartame and saccharin offer a safe, low-calorie option for most people. However, specific groups, including pregnant women and those with phenylketonuria, should avoid certain sweeteners.
Area of Science:
- Nutrition Science
- Food Chemistry
Background:
- Widespread public concern exists regarding sugar and artificial sweetener consumption.
- Physicians require guidance to address patient inquiries on sugar substitutes effectively.
Purpose of the Study:
- To clarify the safety and appropriate use of common sugar substitutes.
- To identify specific population groups that should avoid certain sweeteners.
Main Methods:
- Literature review on the safety profiles of aspartame and saccharin.
- Analysis of dietary guidelines and recommendations for specific populations.
Main Results:
- Aspartame and saccharin are safe for the general population in a balanced diet, offering reduced calories and cariogenic potential.
- Pregnant women and young children should avoid saccharin.
- Individuals with phenylketonuria must avoid aspartame.
Conclusions:
- Sugar substitutes can aid dietary compliance for overweight and diabetic individuals.
- Informed use of aspartame and saccharin supports healthier eating habits for the general population.
More Related Videos
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...